37 results found.

Myelodysplastic Syndromes, or Leukemia, Myelomonocytic, Chronic Clinical Trial using Azacitidine; Volasertib

Boehringer Ingelheim - Recruiting 18 years or older.
- An Open Label Phase I Dose Escalation Trial to Investigate the Maximum Tolerated Dose, Safety, Pharmacokinetics and Efficacy of Intravenous Volasertib in Combination With Subcutaneous Azacitidine in Patients With Previously Untreated High-risk Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML) Ineligible for High-intensity Therapy.
Azacitidine; Volasertib

Leukemia, or Myelodysplastic Syndromes Clinical Trial using filgrastim; busulfan; cyclosporine; fludarabine phosphate; melphalan; mycophenolate mofetil; umbilical cord blood transplantation

Masonic Cancer Center, University of Minnesota - Recruiting N/A to 2 years.
- Hematopoietic Cell Transplantation in the Treatment of Infant Leukemia Using Double Umbilical Cord Transplantation.
filgrastim; busulfan; cyclosporine; fludarabine phosphate; melphalan; mycophenolate mofetil; umbilical cord blood transplantation

Transfusional Iron Overload, Thalassemia Major, Sickle Cell Disea Clinical Trial using Hepatic biomagnetic susceptibility measurement

Columbia University - Recruiting 5 years to 80 years.
- High-Tc Susceptometer to Monitor Transfusional Iron Overload (NSR Device).
Hepatic biomagnetic susceptibility measurement

Acute Myeloid Leukemia (AML), or Myelodysplastic Syndrome (MDS) Clinical Trial

Fred Hutchinson Cancer Research Center - Recruiting 18 years to 80 years.
- Feasibility and Outcomes of Allogeneic Hematopoietic Cell Transplantation (HCT) Compared to Conventional Chemotherapy for Older and Medically Infirm Patients Diagnosed With Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes: A Prospective Observational Study.

Myelodysplastic Syndrome Clinical Trial using Oral Azacitidine; Placebo

Celgene Corporation - Recruiting 18 years or older.
- A Phase 3, Multicenter, Randomized, Double-blind Study to Compare the Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care Versus Placebo Plus Best Supportive Care in Subjects With Red Blood Cell Transfusion-dependent Anemia and Thrombocytopenia Due to IPSS Lower-risk Myelodysplastic Syndromes.
Oral Azacitidine; Placebo

Myelodysplastic Syndromes (MDS), or Acute Myelogenous Leukemia (A Clinical Trial using low dose 5'-azacitidine

Memorial Sloan-Kettering Cancer Center - Recruiting 1 year to 75 years.
- A Single Arm Phase II Trial of Maintenance Low Dose 5'-Azacitidine Post T Cell Depleted Allogeneic Stem Cell Transplantation for Patients With Myelodysplastic Syndrome and Acute Myelogenous Leukemia With High Risk for Post-Transplant Relapse.
low dose 5'-azacitidine

Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Clinical Trial using pravastatin sodium; idarubicin; cytarabine; laboratory biomarker analysis

Fred Hutchinson Cancer Research Center - Recruiting 18 years to 74 years.
- Idarubicin, Cytarabine and Pravastatin (IAP) for Induction of Newly Diagnosed Acute Myeloid Leukemia (AML).
pravastatin sodium; idarubicin; cytarabine; laboratory biomarker analysis

Anemia, Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic L Clinical Trial using Sotatercept

Celgene Corporation - Recruiting 18 years or older.
- An Open-label, Randomized, Phase 2, Parallel, Dose-ranging, Multicenter Study of Sotatercept for the Treatment of Patients With Anemia and Low- or Intermediate-1 Risk Myelodysplastic Syndromes or Non-proliferative Chronic Myelomonocytic Leukemia (CMML)..
Sotatercept

Myeldysplastic Syndrome (MDS), Chronic Myelomonocytic Leukemia, B Clinical Trial using Clofarabine; Lenalidomide

National Institutes of Health Clinical Center (CC) - Recruiting 18 years or older.
- Clofarabine Followed by Lenalidomide for Treatment of High Risk Myelodysplastic Syndromes and Acute Myeloid Leukemia.
Clofarabine; Lenalidomide

Myelodysplastic Syndromes, or Thrombocytopenia Clinical Trial using Eltrombopag

National Institutes of Health Clinical Center (CC) - Recruiting 18 years or older.
- A Pilot Study of a Thrombopoietin-Receptor Agonist (TPO-R Agonist), Eltrombopag, in Patients With Low to Int-2 Risk Myelodysplastic Syndrome (MDS).
Eltrombopag

Myelodysplastic Syndromes Clinical Trial using Group 2: Placebo; Group 1: Epoetin alfa

Janssen-Cilag International NV - Recruiting 18 years or older.
- A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Evaluating Epoetin Alfa Versus Placebo in Anemic Patients With IPSS Low- or Intermediate-1-Risk Myelodysplastic Syndromes.
Group 2: Placebo; Group 1: Epoetin alfa

Myelodysplastic Syndromes Clinical Trial

Radboud University - Recruiting 18 years or older.
- A Prospective, Multicenter European Registry for Newly Diagnosed Patients With Myelodysplastic Syndromes of IPSS Low and Intermediate-1 Subtypes.

Childhood Acute Lymphoblastic Leukemia in Remission, Childhood Ac Clinical Trial using supersaturated calcium phosphate rinse; placebo; questionnaire administration; quality-of-life assessment

Children's Oncology Group - Recruiting 4 years to 21 years.
- A Randomized Double Blinded Trial of Topical Caphosol to Prevent Oral Mucositis in Children Undergoing Hematopoietic Stem Cell Transplantation.
supersaturated calcium phosphate rinse; placebo; questionnaire administration; quality-of-life assessment

Accelerated Phase Chronic Myelogenous Leukemia, Acute Myeloid Leu Clinical Trial using ex vivo-expanded cord blood progenitor cell infusion; umbilical cord blood transplantation; double-unit umbilical cord blood transplantation; fludarabine phosphate; cyclophosphamide; total-body irradiation; cyclosporine; mycophenolate mofetil; laboratory biomarker analysis

Fred Hutchinson Cancer Research Center - Recruiting 6 Months to 45 years.
- Multi-center, Open-label Randomized Study of Single or Double Myeloablative Cord Blood Transplantation With or Without Infusion of Off-The-shelf ex Vivo Expanded Cryopreserved Cord Blood Progenitor Cells in Patients With Hematologic Malignancies.
ex vivo-expanded cord blood progenitor cell infusion; umbilical cord blood transplantation; double-unit umbilical cord blood transplantation; fludarabine phosphate; cyclophosphamide; total-body irradiation; cyclosporine; mycophenolate mofetil; laboratory biomarker analysis

Myeloproliferative Disorders, Blood Cancer, or Myelodysplastic Sy Clinical Trial using Total Lymphoid Irradiation (TLI); Anti-Thymocyte Globulin as Conditioning (ATG)

Stanford University - Recruiting 49 years to 75 years.
- Total Lymphoid Irradiation and Anti-Thymocyte Globulin as Conditioning for Non-Myeloablative Allogeneic Hematopoietic Cell Transplantation for the Treatment of Myelodysplastic Syndromes and Myeloproliferative Disorders (Except CML).
Total Lymphoid Irradiation (TLI); Anti-Thymocyte Globulin as Conditioning (ATG)

Adult Acute Basophilic Leukemia, Adult Acute Eosinophilic Leukemi Clinical Trial using decitabine; mitoxantrone hydrochloride; etoposide; cytarabine; laboratory biomarker analysis

Fred Hutchinson Cancer Research Center - Recruiting 18 years or older.
- Mitoxantrone, Etoposide, and Cytarabine (MEC) Following Epigenetic Priming With Decitabine in Adults With Relapsed/Refractory Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndromes (MDS): A Phase 1/2 Study.
decitabine; mitoxantrone hydrochloride; etoposide; cytarabine; laboratory biomarker analysis

Myelodysplastic Syndromes Clinical Trial using Lenalidomide

Washington University School of Medicine - Recruiting 18 years or older.
- Phase II Trial of High Dose Lenalidomide in Patients With Myelodysplastic Syndrome Refractory to Hypomethylating Agents.
Lenalidomide

MDS, CMML, or AML Clinical Trial using SGI-110

Astex Pharmaceuticals - Recruiting 18 years or older.
- A Phase 1-2, Dose Escalation, Multicenter Study of Two Subcutaneous Regimens of SGI-110, a DNA Hypomethylating Agent, in Subjects With Intermediate or High-Risk Myelodysplastic Syndromes (MDS) or Acute Myelogenous Leukemia (AML).
SGI-110

Thrombocytopaenia Clinical Trial using eltrombopag; placebo

GlaxoSmithKline - Recruiting 18 years or older.
- A Three-part Study of Eltrombopag in Thrombocytopenic Subjects With Myelodysplastic Syndromes or Acute Myeloid Leukemia (Part 1: Open-label, Part 2: Randomized, Double-blind, Part 3: Extension).
eltrombopag; placebo

Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adul Clinical Trial using DEC-205/NY-ESO-1 fusion protein CDX-1401; poly ICLC; decitabine; laboratory biomarker analysis

Roswell Park Cancer Institute - Recruiting 18 years or older.
- A Phase I Study of DEC205mAb-NY ESO 1 Fusion Protein (CDX-1401) Given With Adjuvant polyICLC in Conjunction With 5-Aza-2'Deoxycytidine (Decitabine) in Patients With MDS or Low Blast Count AML.
DEC-205/NY-ESO-1 fusion protein CDX-1401; poly ICLC; decitabine; laboratory biomarker analysis

Chronic Myeloproliferative Disorders, Graft Versus Host Disease, Clinical Trial using filgrastim; allogeneic bone marrow transplantation; peripheral blood stem cell transplantation

National Cancer Institute (NCI) - Recruiting 16 years to 65 years.
- A Randomized Multicentre Study Comparing G-CSF Mobilized Peripheral Blood and G-CSF Stimulated Bone Marrow in Patients Undergoing Matched Sibling Transplantation for Hematologic Malignancies.
filgrastim; allogeneic bone marrow transplantation; peripheral blood stem cell transplantation

Childhood Langerhans Cell Histiocytosis, Fanconi Anemia, Leukemia Clinical Trial using anti-thymocyte globulin; busulfan; cyclophosphamide; fludarabine phosphate; melphalan; methylprednisolone; radiation therapy

National Cancer Institute (NCI) - Recruiting N/A to 21 years.
- The Use Of Umbilical Cord Blood As A Source Of Hematopoietic Stem Cells.
anti-thymocyte globulin; busulfan; cyclophosphamide; fludarabine phosphate; melphalan; methylprednisolone; radiation therapy

Leukemia Clinical Trial using E7070; Idarubicin; Cytarabine; Dexamethasone

M.D. Anderson Cancer Center - Recruiting 18 years or older.
- A Phase 2 Study of E7070, Idarubicin and Cytarabine in Patients With Relapsed or Refractory Acute Myeloid Leukemia and High-risk Myelodysplastic Syndromes.
E7070; Idarubicin; Cytarabine; Dexamethasone

Acute Myeloid Leukemia, or Myelodysplastic Syndromes Clinical Trial using CD8+ T-cell depleted donor lymphocyte infusion

National University Hospital, Singapore - Recruiting 21 years to 90 years.
- Preemptive CD8+ T-cell Depleted Donor Lymphocyte Infusion (DLI) Following Nonmyeloablative Stem Cell Transplantation (NMT) for Acute Myeloid Leukemia (AML) or High Risk Myelodysplastic Syndrome (MDS).
CD8+ T-cell depleted donor lymphocyte infusion

Leukemia, Myeloid, Acute, or Myelodysplastic Syndromes Clinical Trial using decitabine

Washington University School of Medicine - Recruiting 18 years or older.
- Genomic Predictors of Decitabine Response in AML/MDS.
decitabine

Myelodysplastic Syndromes Clinical Trial using vosaroxin; Azacitidine

Washington University School of Medicine - Recruiting 18 years or older.
- A Phase I Study of Vosaroxin Plus Azacitidine for Patients With Myelodysplastic Syndrome.
vosaroxin; Azacitidine

Thalassemia, Non-transfusion Dependent Thalassemia, Myelodysplast Clinical Trial using Single arm MRI test

Novartis - Recruiting 12 years or older.
- An Epidemiological Study to Assess the Prevalence of Iron Overload Using MRI in Patients With Transfusional Siderosis (TIMES Study).
Single arm MRI test

Myelodysplastic Syndrome Clinical Trial using Decitabine; Clofarabine

M.D. Anderson Cancer Center - Recruiting 18 years or older.
- A Randomized Study of Decitabine Alternating With Clofarabine Versus Decitabine Until Failure in Patients With Higher Risk Myelodysplastic Syndromes (MDS).
Decitabine; Clofarabine

Previously Treated Myelodysplastic Syndromes Clinical Trial using 6,8-bis(benzylthio)octanoic acid

Comprehensive Cancer Center of Wake Forest University - Recruiting 18 years or older.
- A Pilot Study of CPI-613 in Patients With Myelodysplastic Syndrome Who Have Failed Previous Therapy.
6,8-bis(benzylthio)octanoic acid

Leukemia, Myeloid, Acute, or Myelodysplastic Syndromes Clinical Trial using Azacitidine; Pre-DLI Salvage Chemotherapy; Donor Leukocyte Infusion (DLI)

Washington University School of Medicine - Recruiting 18 years or older.
- A Phase I Study of the Safety and Feasibility of Azacitidine After Donor Lymphocyte Infusion for Patients With Relapsed Acute Myeloid Leukemia or Myelodysplastic Syndrome After Allogeneic Stem Cell Transplantation.
Azacitidine; Pre-DLI Salvage Chemotherapy; Donor Leukocyte Infusion (DLI)

Leukemia, Acute Myeloid, Leukemia, Lymphoblastic,Acute, or Myelod Clinical Trial using brentuximab vedotin

Washington University School of Medicine - Recruiting 18 years to 65 years.
- A Pilot Study of Brentuximab Vedotin in the Prevention of Graft-Versus-Host Disease (GVHD) After Mismatched Unrelated Allogeneic Stem Cell Transplantation.
brentuximab vedotin

Graft Versus Host Disease, Leukemia, or Myelodysplastic Syndromes Clinical Trial using Fludarabine Phosphate; Tacrolimus; Thiotepa; Total-Body Irradiation (TBI); Magnetic Affinity Cell Sorting; Peripheral Blood Stem Cell Transplantation; Allogeneic Hematopoietic Stem Cell Transplantation; T Cell-Depleted Hematopoietic Stem Cell Transplantation

Yale University - Recruiting 14 years to 55 years.
- A Multi-center Phase II Study of Selective Depletion of CD45RA+ T Cells From Allogeneic Peripheral Blood Stem Cell Grafts for the Prevention of GVHD.
Fludarabine Phosphate; Tacrolimus; Thiotepa; Total-Body Irradiation (TBI); Magnetic Affinity Cell Sorting; Peripheral Blood Stem Cell Transplantation; Allogeneic Hematopoietic Stem Cell Transplantation; T Cell-Depleted Hematopoietic Stem Cell Transplantation

Leukemia, or Myelodysplastic Syndromes Clinical Trial using clofarabine; cytarabine; idarubicin

European Organisation for Research and Treatment of Cancer - EORTC - Recruiting 18 years to 60 years.
- Clofarabine in Combination With a Standard Remission Induction Regimen (AraC and Idarubicin) in Patients 18-60 Years Old With Previously Untreated Intermediate and Bad Risk Acute Myelogenous Leukemia (AML) or High Risk Myelodysplasia (MDS) : a Phase I-II Study of the EORTC-LG and GIMEMA (AML-14A Trial).
clofarabine; cytarabine; idarubicin

Dyskeratosis Congenita, Fanconi Anemia, Myelodysplastic Syndromes Clinical Trial using polymerase chain reaction; flow cytometry; immunologic technique; biopsy

University Hospital Freiburg - Recruiting N/A to 17 years.
- TCR Vbeta Repertoire and PNH Clones in Children With Refractory Cytopenia (RC). An Open Nonrandomised Multi-Center Prospective Study.
polymerase chain reaction; flow cytometry; immunologic technique; biopsy

Myelodysplastic Syndromes, or Juvenile Myelomonocytic Leukemia Clinical Trial

University Hospital Freiburg - Recruiting N/A to 215 Months.
- Prospective Non-randomized Multi-center Study for Epidemiology and Characterization of Myelodysplastic Syndromes (MDS) and Juvenile Myelomonocytic Leucemia (JMML) in Childhood.

Leukemia, or Myelodysplastic Syndromes Clinical Trial using anti-thymocyte globulin; peripheral blood lymphocyte therapy; fludarabine phosphate; methylprednisolone; thiotepa; allogeneic hematopoietic stem cell transplantation; in vitro-treated peripheral blood stem cell transplantation; total-body irradiation

National Cancer Institute (NCI) - Recruiting N/A to 50 years.
- Delayed Infusion of Ex Vivo Anergized Peripheral Blood Mononuclear Cells Following CD34 Selected Peripheral Blood Stem Cell Transplantation From a Haploidentical Donor for Patients With Acute Leukemia and Myelodysplasia.
anti-thymocyte globulin; peripheral blood lymphocyte therapy; fludarabine phosphate; methylprednisolone; thiotepa; allogeneic hematopoietic stem cell transplantation; in vitro-treated peripheral blood stem cell transplantation; total-body irradiation

Myelodysplastic Syndromes Clinical Trial using Bortezomib

Groupe Francophone des Myelodysplasies - Recruiting 18 years or older.
- Phase I/II Study of Bortezomib and Low Dose Cytarabine in the Treatment of High-Risk Myelodysplastic Syndromes.
Bortezomib